Dirk Venter

Statistics

Publications

Citations

H-Index

Active since

2019

Affiliations

Baker Heart and Diabetes Institute(Current)

Universidad de La Frontera

Polish Academy of Sciences

Oregon Health & Science University

Institut universitaire de cardiologie et de pneumologie de Québec

Dirk Venter is an author at Baker Heart and Diabetes Institute specializing in placebo-controlled efficacy assessment, pharmacology, and diabetes pharmacotherapy.

Publications per year

2019–2021

Publications

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 629 citations · Full text

Medicine, Endocrinology, Nephrology +15

Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial

Jo Hardy, Christina Baggott, James Fingleton et al. · The Lancet · 2019 · 276 citations

Pharmacy, Internal Medicine, Pharmacotherapy +9

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Monoclonal Antibody MHAA4549A in Patients With Acute Uncomplicated Influenza A Infection

Jeremy J. Lim, Sadia Dar, Dirk Venter et al. · Open Forum Infectious Diseases · 2021 · 16 citations · Full text

Pharmacy, Infectious Diseases, Pharmacology +17

1–4 of 4